GEHC · GE Healthcare Technologies Inc
Price
Snapshot
50 fields · last close| Market Cap | $31.42B |
| P/E | 15.83 |
| Float | 450.0M |
| Beta | 0.83 |
| Volatility | 20.7% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 76.6 |
| Price | 69.44 |
| Change | −0.19% |
| Prev Close | 69.57 |
| Open | 71.10 |
| Day Low | 69.45 |
| Day High | 71.32 |
| Avg Vol | 4 |
| Avg $ Vol | $270.1M |
| 52W High | 89.77 |
| 52W Low | 58.75 |
| 52W Pos | 34.5% |
| From High | −22.65% |
| From Low | +18.20% |
| Max DD 1Y | −32.53% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +4.65% |
| SMA 50 | +1.23% |
| SMA 200 | −1.47% |
| RSI (14) | 61.0 |
| Vol 30D | 24.8% |
| Vol 90D | 35.0% |
| 1Y Range | 59–90 |
| Daily bars | 536 |
| Perf Week | +5.83% |
| Perf Month | +7.95% |
| Perf Quarter | +10.73% |
| Perf Half Y | −6.82% |
| Perf Year | −4.98% |
| Perf YTD | −16.16% |
| Prev Day | −0.19% |
| Clavix | B |
| Debt / Eq | 0.96 |
| Curr Ratio | 1.37 |
| Int Cover | 7.9× |
| FCF Margin | 7.4% |
| Rev Growth | +4.8% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 25 / 49 |
What GEHC does
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally.
The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women’s health products.
The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women’s health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products.
The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products.
The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries.
The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes.
The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022.
The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Clavix risk grade
regraded every trading dayGEHC grades B, 76.6 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (60, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 25 of 49 in Health Care by Clavix score.
How rough the ride is
| GEHC | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.83 | 0.84 |
| Volatilityannualized | 20.7% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −32.5% | — |
| Typical daily movemedian absolute daily change | 1.14% | — |
| Days beyond ±3%of the last 252 sessions | 29 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GEHC | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.83 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GEHC | |
|---|---|
| 1 week | +5.8% |
| 1 month | +8.0% |
| Year to date | −16.2% |
| 1 year | −5.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GEHC | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 30 Jul |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 2 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| GEHC | |
|---|---|
| Revenue growthyear over year | +4.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGE HealthCare expanded its PETtrace Solid Target Platform to support Copper-64 production and received CE Mark approval for its MINItrace Magni cyclotron, strengthening its role in supplying PET radioisotopes and theranostics research infrastructure.
An article examining the bullish case for GE HealthCare following its spinoff from General Electric, noting the company's evolution from a hardware developer into an AI-led, higher-margin medical technology business with a growing order backlog. The full article text is truncated, so specific details on the pharmaceutical diagnostics strategy, performance figures, or segment results are not available.
Barclays upgraded GE HealthCare Technologies (GEHC) to a 'strong-buy' rating on Wednesday. The article provides no price target or reasoning for the upgrade.
GE HealthCare voluntarily recalled its Centricity PACS imaging software worldwide after a bug was found that could link migrated patient images to the wrong person, risking misdiagnosis across 1,443 systems. In the same week, the company raised its quarterly dividend by 14% to $0.04 per share.
Citigroup cut its price target on GEHC from $75 to $71 and assigned a neutral rating in a research note on Monday.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| DXCM | Dexcom Inc | B | $32.47B | 32.48 | 1.44 | Compare |
| RMD | Resmed Inc | B+ | $33.61B | 22.06 | 0.77 | Compare |
| CNC | Centene Corp | B | $34.16B | — | 1.08 | Compare |
| ALC | Alcon AG | B+ | $27.54B | 40.81 | 1.07 | Compare |
| DGX | Quest Diagnostics Inc | A- | $25.94B | 24.42 | 0.56 | Compare |
| LH | Labcorp Holdings Inc | A- | $25.79B | 25.73 | 0.89 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $44.15B | 38.74 | 1.55 | Compare |
| STE | STERIS plc | A- | $21.71B | 26.97 | 0.88 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.